{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:27:05Z","timestamp":1787840825171,"version":"build-2784847793"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":2158,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The aim of this study was to test whether autoantibodies against neurologic surface Ags are found in nonneurologic autoimmune diseases, indicating a broader loss of tolerance. Patient and matched healthy donor (HD) sera were derived from four large cohorts: 1) rheumatoid arthritis (RA) (n = 194, HD n = 64), 2) type 1 diabetes (T1D) (n = 200, HD n = 200), 3) systemic lupus erythematosus (SLE) (n = 200, HD n = 67; neuro-SLE n = 49, HD n = 33), and 4) a control cohort of neurologic autoimmunity (relapsing-remitting multiple sclerosis [MS] n = 110, HD n = 110; primary progressive MS n = 9; secondary progressive MS n = 10; neuromyelitis optica spectrum disorders n = 15; and other neurologic disorders n = 26). Screening of 1287 unique serum samples against four neurologic surface Ags (myelin oligodendrocyte glycoprotein, aquaporin 4, acetylcholine receptor, and muscle-specific kinase) was performed with live cell\u2013based immunofluorescence assays using flow cytometry. Positive samples identified in the screening were further validated using autoantibody titer quantification by serial dilutions or radioimmunoassay. Autoantibodies against neurologic surface Ags were not observed in RA and T1D patients, whereas SLE patients harbored such autoantibodies in rare cases (2\/200, 1%). Within the CNS autoimmunity control cohort, autoantibodies against aquaporin 4 and high-titer Abs against myelin oligodendrocyte glycoprotein were, as expected, specific for neuromyelitis optica spectrum disorders. We conclude that neurologic autoantibodies do not cross disease barriers in RA and T1D. The finding of mildly increased neurologic autoantibodies in SLE may be consistent with a broader loss of B cell tolerance in this form of systemic autoimmunity.<\/jats:p>","DOI":"10.4049\/jimmunol.1801295","type":"journal-article","created":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T22:49:08Z","timestamp":1551480548000},"page":"2210-2219","source":"Crossref","is-referenced-by-count":28,"title":["Autoantibodies against Neurologic Antigens in Nonneurologic Autoimmunity"],"prefix":"10.1093","volume":"202","author":[{"given":"Panos","family":"Stathopoulos","sequence":"first","affiliation":[{"name":"Department of Neurology, Yale School of Medicine , New Haven, CT 06511"},{"name":"Department of Immunobiology, Yale School of Medicine , New Haven, CT 06511"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Chastre","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale School of Medicine , New Haven, CT 06511"},{"name":"Department of Immunobiology, Yale School of Medicine , New Haven, CT 06511"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Waters","sequence":"additional","affiliation":[{"name":"Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford , Oxford OX1 2JD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarosh","family":"Irani","sequence":"additional","affiliation":[{"name":"Oxford Autoimmune Neurology Group, Nuffield Department of Clinical Neurosciences, University of Oxford , Oxford OX1 2JD ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0107-4103","authenticated-orcid":false,"given":"Miriam L","family":"Fichtner","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale School of Medicine , New Haven, CT 06511"},{"name":"Department of Immunobiology, Yale School of Medicine , New Haven, CT 06511"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2037-9420","authenticated-orcid":false,"given":"Erik S","family":"Benotti","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale School of Medicine , New Haven, CT 06511"},{"name":"Department of Immunobiology, Yale School of Medicine , New Haven, CT 06511"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9308-237X","authenticated-orcid":false,"given":"Joel M","family":"Guthridge","sequence":"additional","affiliation":[{"name":"Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation , Oklahoma City, OK 73104"},{"name":"Oklahoma Clinical and Translational Science Institute, University of Oklahoma Health Sciences Center , Oklahoma City, OK 73104"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Seifert","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Colorado School of Medicine , Aurora, CO 80045"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Nowak","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale School of Medicine , New Haven, CT 06511"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9005-1885","authenticated-orcid":false,"given":"Jane H","family":"Buckner","sequence":"additional","affiliation":[{"name":"Translational Research Program, Benaroya Research Institute at Virginia Mason , Seattle, WA 98101"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V Michael","family":"Holers","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Colorado School of Medicine , Aurora, CO 80045"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9574-7355","authenticated-orcid":false,"given":"Judith A","family":"James","sequence":"additional","affiliation":[{"name":"Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation , Oklahoma City, OK 73104"},{"name":"Oklahoma Clinical and Translational Science Institute, University of Oklahoma Health Sciences Center , Oklahoma City, OK 73104"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Hafler","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale School of Medicine , New Haven, CT 06511"},{"name":"Department of Immunobiology, Yale School of Medicine , New Haven, CT 06511"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7056-419X","authenticated-orcid":false,"given":"Kevin C","family":"O\u2019Connor","sequence":"additional","affiliation":[{"name":"Department of Neurology, Yale School of Medicine , New Haven, CT 06511"},{"name":"Department of Immunobiology, Yale School of Medicine , New Haven, CT 06511"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,15]]},"reference":[{"key":"2025030417561573800_r1","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"2025030417561573800_r2","doi-asserted-by":"crossref","first-page":"797","DOI":"10.7326\/0003-4819-146-11-200706050-00008","article-title":"Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis","volume":"146","author":"Nishimura","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"2025030417561573800_r3","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1159\/000060541","article-title":"Autoantibodies in human diabetes","volume":"4","author":"Pietropaolo","year":"2001","journal-title":"Curr. Dir. Autoimmun."},{"key":"2025030417561573800_r4","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"2025030417561573800_r5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"2025030417561573800_r6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"2025030417561573800_r7","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1212\/NXI.0000000000000131","article-title":"Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis","volume":"2","author":"Chalmoukou","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"2025030417561573800_r8","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nm1488","article-title":"Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein","volume":"13","author":"O\u2019Connor","year":"2007","journal-title":"Nat. Med."},{"key":"2025030417561573800_r9","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1001\/jamaneurol.2017.4601","article-title":"Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease","volume":"75","author":"Hacohen","year":"2018","journal-title":"JAMA Neurol."},{"issue":"9","key":"2025030417561573800_r10","first-page":"S67","article-title":"Pediatric acquired CNS demyelinating syndromes: features associated with multiple sclerosis","volume":"87","author":"Hintzen","year":"2016","journal-title":"Neurology"},{"key":"2025030417561573800_r11","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"2025030417561573800_r12","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol."},{"key":"2025030417561573800_r13","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1212\/WNL.0b013e318228c0b1","article-title":"Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis","volume":"77","author":"Pr\u00f6bstel","year":"2011","journal-title":"Neurology"},{"key":"2025030417561573800_r14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"key":"2025030417561573800_r15","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1056\/NEJM197510092931508","article-title":"Acetylcholine receptor antibodies in myasthenia gravis","volume":"293","author":"Appel","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"2025030417561573800_r16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature13835","article-title":"Genetic and epigenetic fine mapping of causal autoimmune disease variants","volume":"518","author":"Farh","year":"2015","journal-title":"Nature"},{"key":"2025030417561573800_r17","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1001\/archneurol.2007.17","article-title":"Neuromyelitis optica and non organ-specific autoimmunity","volume":"65","author":"Pittock","year":"2008","journal-title":"Arch. Neurol."},{"key":"2025030417561573800_r18","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/art.24833","article-title":"A prospective approach to investigating the natural history of preclinical rheumatoid arthritis (RA) using first-degree relatives of probands with RA","volume":"61","author":"Kolfenbach","year":"2009","journal-title":"Arthritis Rheum."},{"key":"2025030417561573800_r19","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum."},{"key":"2025030417561573800_r20","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.2337\/dc10-S062","article-title":"Diagnosis and classification of diabetes mellitus. [Published erratum appears in 2010 Diabetes Care 33: e57.]","volume":"33","author":"American Diabetes Association","year":"2010","journal-title":"Diabetes Care"},{"key":"2025030417561573800_r21","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/rheumatology\/keq302","article-title":"The lupus family registry and repository","volume":"50","author":"Rasmussen","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2025030417561573800_r22","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1002\/art.34651","article-title":"Comparison of autoantibody specificities between traditional and bead-based assays in a large, diverse collection of patients with systemic lupus erythematosus and family members","volume":"64","author":"Bruner","year":"2012","journal-title":"Arthritis Rheum."},{"key":"2025030417561573800_r23","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum."},{"key":"2025030417561573800_r24","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1002\/1529-0131(199904)42:4<599::AID-ANR2>3.0.CO;2-F","article-title":"The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes","volume":"42","author":"ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature","year":"1999","journal-title":"Arthritis Rheum."},{"key":"2025030417561573800_r25","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"2025030417561573800_r26","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-017-0984-5","article-title":"Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination","volume":"14","author":"Peschl","year":"2017","journal-title":"J. Neuroinflammation"},{"key":"2025030417561573800_r27","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1212\/01.WNL.0000289761.64862.ce","article-title":"Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica","volume":"69","author":"Hinson","year":"2007","journal-title":"Neurology"},{"key":"2025030417561573800_r28","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1212\/NXI.0000000000000011","article-title":"AQP4 autoantibody assay performance in clinical laboratory service","volume":"1","author":"Fryer","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"2025030417561573800_r29","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1093\/brain\/awn092","article-title":"IgG1 antibodies to acetylcholine receptors in \u2018seronegative\u2019 myasthenia gravis","volume":"131","author":"Leite","year":"2008","journal-title":"Brain"},{"key":"2025030417561573800_r30","doi-asserted-by":"crossref","first-page":"e80695","DOI":"10.1371\/journal.pone.0080695","article-title":"MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters","volume":"8","author":"Koneczny","year":"2013","journal-title":"PLoS One"},{"key":"2025030417561573800_r31","doi-asserted-by":"crossref","first-page":"e94263","DOI":"10.1172\/jci.insight.94263","article-title":"Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis","volume":"2","author":"Stathopoulos","year":"2017","journal-title":"JCI Insight"},{"key":"2025030417561573800_r32","doi-asserted-by":"crossref","first-page":"e89","DOI":"10.1212\/NXI.0000000000000089","article-title":"MOG cell-based assay detects non-MS patients with inflammatory neurologic disease","volume":"2","author":"Waters","year":"2015","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"2025030417561573800_r33","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jns.2009.03.020","article-title":"MuSK-antibody-positive myasthenia gravis in a South Asian population","volume":"284","author":"Chang","year":"2009","journal-title":"J. Neurol. Sci."},{"key":"2025030417561573800_r34","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.expneurol.2015.01.011","article-title":"Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases","volume":"270","author":"Rodriguez Cruz","year":"2015","journal-title":"Exp. Neurol."},{"key":"2025030417561573800_r35","article-title":"Autoimmunity to multiple antigens is expanded in at-risk family members beyond the disease specific patterns of the SLE or RA proband","volume-title":"Arthritis Rheumatol.","author":"James","year":"2016"},{"key":"2025030417561573800_r36","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.40356","article-title":"Understanding the antibody repertoire in neuropsychiatric systemic lupus erythematosus and neuromyelitis optica spectrum disorder: do they share common targets?","volume":"70","author":"Mader","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"2025030417561573800_r37","article-title":"Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus","author":"Pr\u00f6bstel","year":"2018","journal-title":"Rheumatology."},{"key":"2025030417561573800_r38","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/acn3.311","article-title":"Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis","volume":"3","author":"Lee","year":"2016","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"2025030417561573800_r39","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1172\/JCI68775","article-title":"Specific peripheral B cell tolerance defects in patients with multiple sclerosis","volume":"123","author":"Kinnunen","year":"2013","journal-title":"J. Clin. Invest."},{"key":"2025030417561573800_r40","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/art.40215","article-title":"Defective early B cell tolerance checkpoints in Sj\u00f6gren\u2019s syndrome patients","volume":"69","author":"Glauzy","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"2025030417561573800_r41","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1177\/1352458517699791","article-title":"Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: a predominantly population-based study","volume":"24","author":"Asgari","year":"2018","journal-title":"Mult. Scler."},{"key":"2025030417561573800_r42","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/art.27337","article-title":"Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sj\u00f6gren\u2019s syndrome","volume":"62","author":"Wandinger","year":"2010","journal-title":"Arthritis Rheum."},{"key":"2025030417561573800_r43","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jneuroim.2015.10.007","article-title":"Anti-aquaporin-4 autoantibodies in systemic lupus erythematosus persist for years and induce astrocytic cytotoxicity but not CNS disease","volume":"289","author":"Alexopoulos","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"2025030417561573800_r44","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1212\/WNL.0b013e3181a82621","article-title":"A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset","volume":"72","author":"Nishiyama","year":"2009","journal-title":"Neurology"},{"key":"2025030417561573800_r45","doi-asserted-by":"crossref","first-page":"eaai9111","DOI":"10.1126\/scitranslmed.aai9111","article-title":"Glucose-regulated protein 78 autoantibody associates with blood-brain barrier disruption in neuromyelitis optica","volume":"9","author":"Shimizu","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"2025030417561573800_r46","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ana.21802","article-title":"Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica","volume":"66","author":"Bennett","year":"2009","journal-title":"Ann. Neurol."},{"key":"2025030417561573800_r47","doi-asserted-by":"crossref","first-page":"486","DOI":"10.3109\/03009742.2011.575077","article-title":"Association between myasthaenia gravis and systemic lupus erythematosus: three case reports and review of the literature","volume":"40","author":"Castrej\u00f3n","year":"2011","journal-title":"Scand. J. Rheumatol."},{"key":"2025030417561573800_r48","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1136\/pgmj.70.828.741","article-title":"The association of systemic lupus erythematosus and myasthenia gravis","volume":"70","author":"Vaiopoulos","year":"1994","journal-title":"Postgrad. Med. J."},{"key":"2025030417561573800_r49","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1212\/WNL.0b013e31825644ff","article-title":"Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients","volume":"78","author":"Leite","year":"2012","journal-title":"Neurology"},{"key":"2025030417561573800_r50","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.msard.2018.12.028","article-title":"Neuromyelitis optica spectrum disorder presenting with concurrent autoimmune diseases","volume":"28","author":"Bibic","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"2025030417561573800_r51","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1093\/brain\/awm027","article-title":"Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese","volume":"130","author":"Matsuoka","year":"2007","journal-title":"Brain"},{"key":"2025030417561573800_r52","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1093\/brain\/awn240","article-title":"Antibody to aquaporin-4 in the long-term course of neuromyelitis optica","volume":"131","author":"Jarius","year":"2008","journal-title":"Brain"},{"key":"2025030417561573800_r53","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"Waters","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2025030417561573800_r54","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bpa.12084","article-title":"Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature","volume":"23","author":"Jarius","year":"2013","journal-title":"Brain Pathol."},{"key":"2025030417561573800_r55","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1212\/01.wnl.0000345066.57745.50","article-title":"NMO-IgG detected in CSF in seronegative neuromyelitis optica","volume":"72","author":"Klawiter","year":"2009","journal-title":"Neurology"},{"key":"2025030417561573800_r56","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clim.2010.11.013","article-title":"Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases","volume":"138","author":"Di Pauli","year":"2011","journal-title":"Clin. Immunol."},{"key":"2025030417561573800_r57","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J. Neuroinflammation"},{"key":"2025030417561573800_r58","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1212\/NXI.0000000000000040","article-title":"Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis","volume":"1","author":"Ramanathan","year":"2014","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"2025030417561573800_r59","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"key":"2025030417561573800_r60","article-title":"Usefulness of MOG-antibody titres at first episode to predict the future clinical course in adults","author":"Cobo-Calvo","year":"2019","journal-title":"J. Neurol."},{"key":"2025030417561573800_r61","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12974-016-0719-z","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement - frequency, presentation and outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"2025030417561573800_r62","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/jnnp-2016-314005","article-title":"Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease","volume":"88","author":"Jury\u0144czyk","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2025030417561573800_r63","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"2025030417561573800_r64","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/jnnp-2017-315998","article-title":"Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases","volume":"88","author":"Hyun","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"2025030417561573800_r65","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11926-014-0419-6","article-title":"Preclinical rheumatoid arthritis (autoantibodies): an updated review","volume":"16","author":"Deane","year":"2014","journal-title":"Curr. Rheumatol. Rep."}],"container-title":["The Journal of Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/202\/8\/2210\/61419185\/ji1801295.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jimmunol\/article-pdf\/202\/8\/2210\/61419185\/ji1801295.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T20:01:56Z","timestamp":1741118516000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jimmunol\/article\/202\/8\/2210\/7952314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,4,15]]}},"URL":"https:\/\/doi.org\/10.4049\/jimmunol.1801295","relation":{},"ISSN":["0022-1767","1550-6606"],"issn-type":[{"value":"0022-1767","type":"print"},{"value":"1550-6606","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,4]]},"published":{"date-parts":[[2019,4]]}}}